Torrent Pharmaceuticals gets rights to generic of Pfizer’s oral Covid-19 treatment

Torrent Pharmaceuticals gets rights to generic of Pfizer’s oral Covid-19 treatment

Torrent Pharmaceuticals has entered into a licensing agreement with Medicine Patent Pool (MPP) for manufacturing and commercializing the generic version of Pfizer’s oral Covid-19 treatment. Pfizer’s oral Covid-19 treatment is made up of PAXLOVID (nirmatrelvir), which inhibits a SARS-CoV-2 protein to prevent the SARSCoV-2 virus from replicating and ritonavir, which slows down the breakdown of […]

SMS Pharmaceuticals gets license to Pfizer Covid‐19 drug nirmatrelvir

SMS Pharmaceuticals gets license to Pfizer Covid‐19 drug nirmatrelvir

SMS Pharmaceuticals has secured a non‐exclusive license via the Medicines Patent Pool (MPP) for manufacturing nirmatrelvir, an oral antiviral Covid‐19 drug developed by Pfizer, to increase wider access to treatment in 95 low‐ and middle‐ income countries. Previously, Pfizer had announced that the clinical trial of PAXLOVID (nirmatrelvir tablets and ritonavir tablets) demonstrated significant reduction […]

Pfizer gets FDA breakthrough status for RSVpreF RSV vaccine candidate

Pfizer gets FDA breakthrough status for RSVpreF RSV vaccine candidate

Pfizer has secured breakthrough therapy designation for its respiratory syncytial virus (RSV) vaccine candidate — PF-06928316 (RSVpreF) from the US Food and Drug Administration (FDA) for the prevention of RSV-associated lower respiratory tract illness in infants from the time of birth up to six months by active immunization of pregnant women. According to Pfizer, the […]

Alembic Pharmaceuticals gets FDA approval for Toviaz generic

Alembic Pharmaceuticals gets FDA approval for Toviaz generic

Alembic Pharmaceuticals said that it has secured tentative approval from the US Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for its generic drug product Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. The tentatively approved product is the generic of Pfizer’s Toviaz Extended-Release Tablets, 4 mg and 8 mg. […]

Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn

Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn

US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion in an all-cash deal. The portfolio of Trillium Therapeutics has biologics that have been designed to boost the ability of patients’ innate immune systems for detecting and killing cancer cells. […]

Microbiome company Vedanta Biosciences raises $68m in Series D

Microbiome company Vedanta Biosciences raises $68m in Series D

Vedanta Biosciences, a clinical-stage microbiome company founded by PureTech Health, has raised $68 million in a Series D financing round led by affiliates of Magnetar Capital. The Cambridge-based company is using defined bacterial consortia manufactured from clonal cell banks for developing a new category of oral therapies for the treatment of immune-mediated diseases. Other participants […]